Nigel Hacking, consultant radiologist, Southampton University Hospitals NHS Trust, Southampton, UK, spoke to Interventional News about using polyvinyl alcohol foam embolization particles (Cook) for prostatic artery embolization in younger men with benign prostatic hyperplasia. The data were presented at GEST 2013 (May, Prague, Czech Republic).
BTG announced on 30 July that the National Institute for Health and Clinical Excellence (NICE) has issued guidance recommending the use of selective internal radiation therapy (SIRT), which includes TheraSphere, for patients with liver cancer across the NHS.
Patrice Bergeron, Hôpital Privé Residence du Parc, Marseille, France, presented initial results of a new device used in the treatment of peripheral arterial disease at the Multidisciplinary European Endovascular Therapy (MEET) Congress (9–11 June 2013, Rome, Italy). The new balloon deploys a microneedle into the adventitia and diffuses anti-inflammatory drug into the arterial wall.
Reverse Medical corporation has announced FDA clearance for US commercialisation of their MVP microvascular plus system for peripheral artery embolization, and the first US clinical cases. The MVP system indication for use is to obstruct or reduce the rate of blood flow in the peripheral vasculature.
Final clinical outcomes from the first and longest-running renal denervation clinical study with the Symplicity renal denervation system (Medtronic) were presented during the European Society of Cardiology congress and have been accepted for publication in The Lancet.
Thomas Vogl, Institute of Diagnostic and Interventional Radiology, Goethe University, Frankfurt, spoke at ECIO (19–22 June, Budapest Hungary) about novel lung ablative techniques and the evidence for combination ablative therapies.
St Jude Medical has announced that it has received CE mark approval for the next generation of its EngliHTN renal denervation system. It says the new system has a total ablation time of approximately four minutes, which is an 80% reduction in total ablation time compared with the first-generation system’s time of approximately 24 minutes.
A small study published online ahead of print on 26 August 2013 in the Journal of Vascular and Interventional Radiology (JVIR) suggests that cone-beam CT is a useful technique that can potentially lessen the risk of non-target embolization in prostatic artery embolization.
Data from the multicentre ENRY evaluation of 325 patients, suggest that radioembolization may be a well tolerated and effective option for an increasing population of older patients.
Case reports published in the Journal of Cardiovascular and Interventional Radiology have found that by using the Surefire Infusion System, radioembolization could be successfully performed without the need to protect nearby blood vessels. This is seen as a significant advance that may enable physicians to safely extend liver cancer treatment to patients who were previously deemed untreatable.
The American College of Cardiology (ACC) announced the publication of detailed criteria to help clinicians optimize the appropriate use of certain noninvasive vascular tests when caring for patients with known or suspected disorders of the venous system. Also included are first-time recommendations for when and how to use these tests to plan for or evaluate dialysis access placement. The authors stress that these criteria should not supersede sound clinical judgment for individual patients.
Teleflex Incorporated (Limerick, PA) announced the launch of the Arrow JACC (jugular axillo-subclavian central catheter), which features the company’s Chloragard technology. The device is a small-French size antimicrobial and antithrombogenic catheter that is designed for both acute and long-term use. The Arrow JACC’s Chloragard technology fights thrombosis and infection for up to 30 days and is effective against the full spectrum of bacterial and fungal pathogens. The Arrow JACC received US Food and Drug Administration clearance in November 2012.
In the Journal of the American College of Cardiology (JACC), Mark I. Davis, MD, et al published a systematic review and meta-analysis of sympathetic renal denervation (RDN) to determine the therapy’s current safety and effectiveness as a treatment for resistant hypertension (2013;62:231–241). The investigators noted that RDN is a novel approach that thus far has been evaluated in multiple small studies.
Sirtex Medical and US-based Surefire Medical has announced a sales and marketing partnership to distribute Surefire’s range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets.
An abstract presentation during EuroPCR 2013 (21–24 May, Paris, France) focused on assessing the number and quality of published clinical trials underpinning the wide use of renal denervation in Germany. It strongly made the point that in the past, clinical trial data on the procedure had been scarce and that the long-term durability of treatment effects had not been proven in a large number of patients.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos